Autobio(SH:603658) Sou Hu Cai Jing·2025-07-16 10:58Company Overview - Antu Biology closed at 37.99 yuan, up 1.12%, with a rolling PE ratio of 19.04 times and a total market value of 21.708 billion yuan [1] - The company ranks 42nd in the medical device industry, which has an average PE ratio of 51.87 times and a median of 37.48 times [1] - As of the first quarter of 2025, 10 institutions held shares in Antu Biology, including 6 funds, with a total holding of 43.5189 million shares valued at 18.139 billion yuan [1] Business Performance - Antu Biology specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - The company was listed among the "Top 100 Pharmaceutical Companies in China for 2023" and achieved second place in the "Top 100 Pharmaceutical Enterprises R&D Index" due to its outstanding performance in R&D results and support indices [1] - In the latest performance report for the first quarter of 2025, the company reported revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76%, with a gross profit margin of 65.07% [1] Industry Comparison - The PE ratio of Antu Biology is significantly lower than the industry average of 51.87 times and the median of 37.48 times, indicating potential undervaluation compared to peers [2] - The industry average market value is 108.06 billion yuan, while Antu Biology's market value is 21.708 billion yuan, suggesting a smaller scale within the industry [2]